No Data
No Data
Dezhan Healthcare (000813.SZ): Simcere Glucagon has successfully completed the pilot test on a 100L fermentation tank, and is expected to produce and sell raw materials by the end of 2024.
Dezhan Healthcare (000813.SZ) stated during an investor relations event on August 7th that in 2023 the company will focus on a cost-leading strategy and promote the development of biological fermentation through the main production of Simcere Glucagon. The process involves the successful establishment of sequences and strains using a new engineering bacterial system that is simpler to purify and has over 50% less steps in the production route compared to the traditional E. coli technique used by most domestic manufacturers. Currently, the company has successfully conducted a pilot production of Simcere Glucagon on a 100L fermentation tank and expects to sell raw materials from pilot production by the end of 2024.
Dezhan Healthcare (000813.SZ): The promotion of the winning of Nijielie's centralized procurement bid has achieved results, with sales in some winning provinces significantly higher than the agreed procurement volume.
On August 7th, Gelunhui reported that Dezhan Healthcare (000813.SZ) stated during an investor relations event that in the first half of 2023, its 'Nile' product won the bid for the 8th batch of national centralized drug procurement, winning seven provinces including Shanghai, and being retained for supply in seven other provinces such as Guangdong. Currently, the promotion of Nile's winning bid areas has been effective, with sales in some winning provinces significantly higher than the contract amount. At present, in the domestic market of lipid-lowering drugs, atorvastatin calcium still occupies the leading position and its market share is far ahead. As a compound preparation for lowering blood lipids and blood pressure, the 'Nile' product of Dezhan Healthcare currently accounts for a certain proportion of the company's overall sales volume.
Dezhan Healthcare: 2024 Interim Performance Forecast
Dezhan Healthcare (000813.SZ): Expected to have a profit of 8-12 million yuan in the first half of the year.
On July 10th, Grong Hui reported Dezhan Healthcare's (000813.SZ) performance forecast for the first half of 2024. The net income attributable to shareholders of the listed company is expected to be between 8 million yuan and 12 million yuan, which is a significant increase from the loss of 7.5644 million yuan in the same period last year. The net income after deducting non-recurring gains and losses is expected to be between 6.5 million yuan and 9.5 million yuan, compared to a loss of 8.8348 million yuan in the same period last year. The basic earnings per share is expected to be between 0.0037 yuan/share and 0.0055 yuan/share. The company's revenue has increased year-on-year during the reporting period, while the impairment loss of inventory has decreased compared to the previous period, thus greatly improving the overall financial performance of the company.
Dezhan Healthcare (000813.SZ) plans to spend 200-300 million yuan to repurchase shares.
On July 2nd, Gelonhui reported that Dezhan Healthcare (000813.SZ) plans to repurchase the company's issued renminbi ordinary shares (A shares), for the purpose of canceling and reducing the registered capital; the total amount of funds for repurchase is not less than RMB 200 million and not more than RMB 300 million; the price range for this repurchase of shares is no more than RMB 3.59 per share. The implementation period is within 12 months from the date of approval of the share repurchase plan by the shareholders' meeting.
Subdued Growth No Barrier To Dezhan Healthcare Company Limited's (SZSE:000813) Price
No Data